We are pleased to share an important milestone in our commitment to diagnostic excellence. Following our participation in the 2026 NordiQC assessment (Participant 1697), our core immunohistochemistry (IHC) products have demonstrated strong performance.

Proven Quality

The results show that our reagents give consistent, reliable, and repeatable staining. We are proud to have earned "Optimal" scores for two critical markers:

• HER2: Essential for guiding targeted breast cancer treatments.
• MSH2:A key marker for identifying Lynch syndrome and screening for immunotherapy.

Additionally, important indicators such as PAX5, MLH1, CDX2, CALRET, and MUM1 got "Good" ratings, proving they work well across breast, GI, and other tumors.

Why NordiQC Matters

NordiQC is an ISO 17043-accredited proficiency testing program, recognized as the world's most rigorous external quality assessment scheme for diagnostic IHC.Their assessments are designed to ensure that laboratories worldwide can trust their diagnostic results.

Advancing Laboratory Performance

This launch represents more than a quality score—it reflects our commitment to the reliability your laboratory depends on. Whether supporting Lynch syndrome screening or guiding breast cancer therapy selection, our NordiQC-validated reagents deliver consistent, trustworthy staining results across every slide.

Click www.talentdiagnostics.com to explore our full portfolio of assessed antibodies and enhance your laboratory's diagnostic precision.